Date: 06/18/2025

by: Wenjie Cheng,Chaolan Pan, Zhe Sun, Peiyi Sun, Jiawen Li, Zhirong Yao, Xiaoxiao WangJia Zhang, Jia Zhang

This case report details the successful treatment of a child with epidermolytic ichthyosis using Vunakizumab, China’s first domestically-developed and approved anti-IL-17A monoclonal antibody. After treatment, the patient’s desquamation, erythema, and itching symptoms were significantly alleviated, and inflammatory factors normalized, demonstrating the drug’s remarkable efficacy.  Read more here https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1574255/full